associate sponsors


Lupin receives USFDA nod for generic Alzheimer treatment drug

New Delhi: Drug major Lupin Thursday said it has received approval from the US health regulator to market its memantine hydrochloride extended-release capsules, used in treating Alzheimer's disease.


The company has received final approval for the product in strengths of 7 mg, 14 mg, 21 mg, and 28 mg from the US Food and Drug Administration (USFDA), Lupin Ltd said in a regulatory filing.

The Mumbai-based company's product is a generic version of Allergan's Namenda XR capsules which are indicated for treatment of moderate to severe dementia of the Alzheimer's type.

According to IMS MAT June 2016 sales data Namenda XR capsules had US sales of $1.22 billion.

Shares of Lupin today ended at Rs 1,469.50 apiece on the BSE, down 3.10 percent from previous close.

Updated Date: Sep 29, 2016 18:02 PM

Also Watch

Social Media Star: Abhishek Bachchan, Varun Grover reveal how they handle selfies, trolls and broccoli
  • Monday, July 16, 2018 It's a Wrap: Soorma star Diljit Dosanjh and Hockey legend Sandeep Singh in conversation with Parul Sharma
  • Monday, July 16, 2018 Watch: Dalit man in Uttar Pradesh defies decades of prejudice by taking out baraat in Thakur-dominated Nizampur village
  • Monday, July 16, 2018 India's water crisis: After govt apathy, Odisha farmer carves out 3-km canal from hills to tackle scarcity in village
  • Sunday, July 15, 2018 Maurizio Sarri, named as new Chelsea manager, is owner Roman Abramovich's latest gamble in quest for 'perfect football'

Also See